Table 2.
Comparison of patient characteristics of DO-IT Registry (date) with ICD arms of MADIT II and SCD-HeFT Trial
| Patient characteristics | DO-IT (n = 1,461a) | DO-IT (n = 1,308, 153 patients excluded) | SCD-HeFT (n = 829) |
MADIT II (n = 742) |
|---|---|---|---|---|
| Age (years) | ||||
| Mean (SD) | 66 (10) | 66 (10) | 64 (10) | |
| Median (IQR) | (68) (60–73) | (68) (60–73) | 60 (52–68) | |
| Men (%) | 73 | 72 | 77 | 84 |
| LVEF | ||||
| Mean (SD) | 26 (6) | 26 (6) | 23 (5) | |
| Median (IQR) | 27 (21–30) | 26 (21–30) | 24 (19–30) | |
| NYHA | ||||
| I (%) | 14 | 9 | 35 | |
| II (%) | 61 | 65 | 70 | 35 |
| III (%) | 22 | 23 | 30 | 25 |
| (%) | <1 | 5 | ||
| Unknown (%) | 3 | 3 | ||
| Ischaemic cardiomyopathy (%) | 56 | 54 | 52 | 100 |
| Diabetes (%) | 27 | 27 | 31 | 33 |
| Hypertension (%) | 43 | 43 | 55 | 53 |
| Atrial fibrillation (%) | 30 | 31 | 17 | 9 |
Data are presented as mean (standard deviation) or median (25th–75th percentiles)
DO-IT Dutch Outcome in ICD therapy,ICD implantable cardioverter-defibrillator, SCD-HeFT Sudden Cardiac Death in Heart Failure Trial, MADIT II Multicentre Automatic Defibrillator Implantation Trial-II, IQR interquartile range, LVEF left ventricular ejection fraction, NYHA New York Heart Association
aPreliminary data as of February 13, 2017.